Efficacy and Safety of CagriSema in Type 2 Diabetes: A Dose- and Comparator-Specific Systematic Review and Bayesian Meta-Analysis.
CagriSema provides substantial glycaemic and body-weight benefits versus placebo and is more evident for body-weight reduction, while comparative gastrointestinal tolerability and discontinuation risk remain uncertain.